Medigen Vaccine Biologics Corporation (TPEX:6547)

Market Cap	14.86B -13.2%
Revenue (ttm)	603.68M -8.9%
Net Income	-289.01M
EPS	-0.90
Shares Out	328.75M
PE Ratio	n/a
Forward PE	69.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,495,994
Open	44.40
Previous Close	44.20
Day's Range	44.30 - 45.60
52-Week Range	33.50 - 61.20
Beta	-0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respirat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 103
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6547

Financial Performance

In 2025, Medigen Vaccine Biologics's revenue was 613.17 million, an increase of 1.24% compared to the previous year's 605.64 million. Losses were -281.71 million, 250.1% more than in 2024.